Impact of a novel community testing pathway for people with suspected COVID-19 in Wales: a cost-minimisation analysis.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
16 08 2020
Historique:
entrez: 18 8 2020
pubmed: 18 8 2020
medline: 9 9 2020
Statut: epublish

Résumé

To compare National Health Service (NHS) organisations' testing pathways for patients with suspected COVID-19 in the community versus standard hospital testing practices. NHS commissioners and services. During the containment phase of the COVID-19 pandemic we developed a community model pathway for COVID-19 testing in Wales with testing teams undertaking swabbing for COVID-19 in individuals' usual place of residence. We undertook a cost-minimisation analysis comparing the costs to the NHS in Wales of community testing for COVID-19 versus standard hospital testing practices and ambulance conveyancing. We analysed data from patients with suspected COVID-19 between January and February 2020 and applied assumptions of costs from national contractual and reference costs for ambulances, staffing and transportation with market costs at the time of publication. 177 patients with suspected COVID-19 underwent community testing via local NHS organisations between January and February 2020 with a mean age of 46.1 (IQR 27.5-56.3). This was 92% of total patients who were tested for COVID-19 during this period. We estimate, compared with standard hospital testing practices, cash savings in improved productivity for the NHS of £24,539 during this time period, in addition to further non-monetised benefits for hospital and ambulance flow. Community testing for COVID-19 in Wales is now an established pathway and continues to bring benefits for patients, local healthcare organisations and the NHS. Further application of this model in other settings and to other infectious diseases may herald promising returns.

Identifiants

pubmed: 32801205
pii: bmjopen-2020-038017
doi: 10.1136/bmjopen-2020-038017
pmc: PMC7430413
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e038017

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMJ. 2020 Feb 14;368:m621
pubmed: 32060015
BMJ. 1993 Sep 18;307(6906):726-8
pubmed: 8401098

Auteurs

Jonny Currie (J)

Public Health Wales, Cardiff, UK jonny.currie@wales.nhs.uk.

James Adamson (J)

Public Health Wales, Cardiff, UK.

Bethan Bowden (B)

Public Health Wales, Cardiff, UK.

Julie Woolls (J)

University Hospital of Wales Healthcare NHS Trust, Cardiff, UK.

Rachel Jones (R)

Public Health Wales Microbiology Swansea, Singleton Hospital, Swansea, UK.

Brendan Healy (B)

University Hospital Wales Heath Park, Cardiff, UK.

David Heyburn (D)

Public Health Wales, Cardiff, UK.

Ananda Giri Shankar (AG)

Public Health Wales, Cardiff, UK.

Robin Howe (R)

Public Health Wales, Cardiff, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH